Business context and reporting period
The supplied filing is Miragen Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2018, filed November 7, 2018. This does not match the request metadata naming Viridian Therapeutics, Inc.; investors should verify the issuer and filing before relying on this summary. Miragen was a clinical-stage biotechnology company developing microRNA-targeted therapies. Its three clinical-stage candidates were cobomarsen, remlarsen and MRG-110. It had no approved products and no product-sales revenue.
Financial performance and position
| Metric | Q3 2018 vs. Q3 2017 | Nine months 2018 vs. 2017 |
|---|---|---|
| Revenue | $0.9m vs. $1.6m | $7.9m vs. $2.8m |
| Research and development | $7.4m vs. $5.0m | $22.2m vs. $14.6m |
| General and administrative | $2.7m vs. $2.5m | $8.4m vs. $8.4m |
| Net loss | $9.0m vs. $5.8m | $22.4m vs. $20.1m |
| Net loss per share, basic and diluted | $0.29 vs. $0.27 | $0.77 vs. $1.11 |
Revenue was collaboration and grant revenue, not product sales. Q3 revenue fell mainly because Servier-reimbursable research activity was lower. Nine-month revenue rose largely from a $3.7m Servier development milestone and higher reimbursements. Q3 operating expenses exceeded revenue by $9.2m; the filing does not present a meaningful product gross margin.
At September 30, 2018, cash and cash equivalents were $31.7m and short-term investments $38.8m, totaling $70.5m in reported liquid resources. Current assets were $75.8m and current liabilities $6.8m. Total liabilities were $15.8m, including a note payable with $10.0m principal outstanding ($1.3m current portion; $8.9m long-term, net). The loan bears interest at prime (5.25% at quarter-end), with principal payments scheduled from 2019 through 2021 and a $0.9m final payment fee due at maturity.
For the nine months, operating cash use was $18.7m; investing cash use was $39.0m, primarily purchases of short-term investments; financing cash provided was $41.9m. Cash declined $15.7m to $31.7m. Financing included approximately $37.9m net proceeds from a February public offering, $2.7m net ATM proceeds and $0.9m from the initial LLS private-placement closing. Common shares outstanding increased to 30.8m from 22.6m at year-end 2017.
Material changes versus the prior comparable period
- Q3 net loss widened by $3.2m as R&D rose $2.4m, principally for cobomarsen SOLAR trial startup and manufacturing, while collaboration revenue declined $0.7m.
- Nine-month net loss widened by $2.3m despite a $5.1m increase in revenue; R&D increased $7.6m, reflecting clinical and manufacturing activity, staff growth and a licensing milestone.
- Cash and cash equivalents decreased from $47.4m at December 31, 2017, while $38.8m of short-term investments were added. Total reported cash and short-term investments therefore rose to $70.5m from $47.4m.
- The February 2018 public offering and other equity issuances increased the share count and supplied substantial funding.
Outlook, commentary and risks
- Management believed cash and short-term investments would fund operations into early 2020, but stated that further capital would be required beyond then. The estimate depends on clinical progress, Servier collaboration performance and access to financing or partnerships.
- Management expected R&D spending and operating losses to increase for at least several years as trials advance. No revenue or earnings guidance was provided.
- Planned development milestones included starting cobomarsen’s Phase 2 SOLAR CTCL trial in Q4 2018, with data expected in the second half of 2020; additional cobomarsen ATLL data in the first half of 2019; remlarsen Phase 2 keloid data in the second half of 2019; and MRG-110 Phase 1 data in 2019. These were expectations, not assured outcomes.
- Principal risks include clinical and regulatory failure or delay, safety and enrollment uncertainties, the unproven microRNA therapeutic approach, reliance on third-party manufacturers and CROs, intellectual-property and licensing risks, and the need for additional capital. Future equity financing could dilute shareholders; debt may impose restrictive covenants.
- Servier may terminate the collaboration under specified conditions; future milestones and royalties depend on development and commercialization. The company also disclosed licensing milestones, royalties and other contingent obligations, but no material legal proceeding was reported.
- Disclosure controls were assessed as effective at a reasonable level of assurance; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the issuer: the filing is for Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Check whether the stated early-2020 cash runway remained achievable against subsequent cash burn, trial costs and financing.
- Track clinical trial starts, enrollment, safety, readouts and regulatory feedback against management’s stated timelines.
- Review additional share issuance, ATM usage and LLS milestone-linked closings for dilution and funding capacity.
- Monitor SVB debt payments, interest and covenants, and Servier’s reimbursement, development and termination provisions.